Clinical trials: Thromboembolic Disorders
Venous Thromboembolism, Cancer
Cancer Associated Thrombosis : What is the Proportion of Patients Ineligible to a Study as CARAVAGGIO
Venous thromboembolism is a common and fatal disease closely related to cancer. The therapeutic challenge is major due to the high risk of recurrent thromboembolism and bleeding in patients with cancer.
- Trial name
- NCT04846556
- Testing
- data collection
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Dyspnea, Pulmonary Embolism
Inhaled Nitric Oxide (iNO) in Post-Pulmonary Embolism (Post-PE)
Following acute pulmonary embolism (PE), up to a third of patients develop post-PE syndrome described as having persistent breathlessness (dyspnea), impaired exercise capacity, and a reduced quality of life.
- Trial name
- NCT04920695
- Testing
- Nitric Oxide
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Dr. Denis O'Donnell
Venous Thromboembolism
Variations in the Hemostatic System Induced by a Standardized Walking Test
Two groups of patients will be compared: One group of patients with a history of venous thromboembolic disease and one group without.
- Trial name
- FAST&THROMBIN (NCT06418633)
- Testing
- 60-minute walking test, Static blood test, Post-effort blood test
- Where
- France
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Nephrotic Syndrome, Thromboembolic Disease
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
The study aims to describe the biochemical coagulation profile and investigate the effect of Low molecular weight heparin and Apixaban on this profile in patients with nephrotic syndrome.
- Trial name
- CAPTAIN (NCT04850378)
- Testing
- Dalteparin, Apixaban
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- University of Aarhus
Hypertension, Pulmonary
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
This is a study to demonstrate the feasibility of an individual dose titration scheme based on the systolic blood pressure with a dose range from 1.0 mg TID to 2.5 mg TID.
- Trial name
- NCT00454558
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 15 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Dilated Cardiomyopathy, Thrombosis
Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy
This study is designed to quantify the ventricular stasis in patients with non-ischemic dilated cardiomyopathy by post-processing of 2D color Doppler echocardiography images in order to establish the relationship between…
- Conditions
- Dilated Cardiomyopathy, Thrombosis, Stroke
- Trial name
- ISBIDCM (NCT03415789)
- Testing
- Doppler echocardiogram exam, Cardiac Magnetic Resonance, Brain Magnetic Resonance
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Atrial Fibrillation, Atrial Flutter
PREdicting Atrial Fibrillation or Flutter
The purpose of this study is to determine, through continuous monitoring with a cardiac monitoring device placed under the skin, the incidence of atrial fibrillation or flutter (AF).
- Trial name
- PREDATE-AF (NCT01851902)
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Keesler Air Force Base Medical Center
Major Orthopaedic Surgery and Renal Impairment
Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.
Fondaparinux is an antithrombotic agent having already received a regulatory approval by the European Authorities in venous thromboembolic event prevention after major orthopaedic surgery, as total hip replacement (THR), total…
- Trial name
- PROPICE (NCT00555438)
- Testing
- fondaparinux 1.5 mg/day
- Where
- 29 sites in France
- Volunteers
- 451 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Thromboembolism, Acute Lymphoblastic Leukemia
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
The study will examine the prevalence of venous thromboembolism in children with acute lymphoblastic leukaemia treated in accordance with NOPHO ALL-2008.
- Trial name
- NCT00982514
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
Venous Thromboembolic Disease
Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study
The implications of the medico-economic impact are essential in the choice of first-line therapists. The economic impact is an important criterion to recommend the privileged use of Direct Oral Anticoagulants (AOD) in first…
- Trial name
- NCT03887806
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Pulmonary Hypertension
ADAMTSL4 in Idiopathic Pulmonary Hypertension and CTEPH
ADAMTSL4 (A disintegrin and metalloproteinase with thrombospondin motifs like) is a member of the ADAMTSL family. ADAMTSL4 is one of the family of 7 ADAMTS-Like proteins, themselves part of the Thrombospondin type 1 repeat (TSR)…
- Trial name
- NCT05478226
- Testing
- drugs or BPA
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Wei Huang
Thromboembolic Venous Disease
New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".
Identify new genetic mutations predisposing to an increased risk of VTE by locating and / or identifying genes involved in subjects at high risk for thrombotic and in whom screening for detectable hereditary thrombophilia was…
- Trial name
- Fit-Génétique (NCT02841085)
- Testing
- Genetic sample
- Where
- France
- Volunteers
- 613 people
- Sponsor
- University Hospital, Brest
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events.
- Trial name
- NCT06619483
- Testing
- BAY3018250 Dose 1, BAY3018250 Dose 2
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Venous Thromboembolic Disease
Observational Prospectif Monocentric Registry of Patients Suffering From VIE
Patients with an episode of VTE (DVT and / or PE) have a mortality rate of 16-21% at 1 year after diagnosis. Morbidity associated with VTE is marked by the risk of recurrence, estimated at 30% and estimated at 29% after 8 years…
- Trial name
- REMOTEV (NCT02188056)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Thromboembolism
HTRS TE Registry (ThromboEmbolism Registry)
The TE Registry is a multi-institutional bioinformatics database for the collection of data relevant to TE. Participating HTRS affiliated study centers may enroll patients and enter data in the TE Registry by completing…
- Trial name
- NCT00266994
- Where
- United States
- Volunteers
- 2,760 people
- Sponsor
- Nationwide Children's Hospital
Myeloma, Venous Thromboembolism
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
To evaluate: the incidence of venous thromboembolic event (VTE) the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an…
- Trial name
- MYELAXAT (NCT02066454)
- Testing
- Apixaban
- Where
- 19 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Grenoble
Pancreatic Cancer
Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer
Venous thromboembolic events are considered to be a prognostic negative factor and small studies showed astonishing survival advantages using heparin as prophylactic treatment to prevent venous thromboembolic events.
- Trial name
- NCT01945879
- Testing
- Enoxaparine
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- CONKO-Studiengruppe
Pulmonary Embolism, Chronic Thromboembolic Pulmonary Hypertension
Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
Potential outcomes after PE occur on a spectrum: complete recovery, exercise intolerance from deconditioning/anxiety, dyspnea from concomitant cardiopulmonary conditions, dyspnea from residual pulmonary vascular occlusion…
- Trial name
- ValidSEARCH (NCT05568927)
- Testing
- SEARCH algorithm
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Venous Thromboembolism
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)
- Trial name
- PREDICARE (NCT03099031)
- Testing
- Tinzaparin
- Where
- France
- Volunteers
- 420 people
- Sponsor
- LEO Pharma
Antiphospholipid Syndrome, Venous Thromboembolism
Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome
Retrospective monocentric registry to evaluate the efficacy and safety of different anticoagulants in patients with thromboembolic antiphospholipid syndrome
- Conditions
- Antiphospholipid Syndrome, Venous Thromboembolism, Arterial Thromboembolism, Major Bleed
- Trial name
- NCT05195372
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Cardioangiologisches Centrum Bethanien